JAK-STAT inhibitors for the treatment of immunomediated diseases

Abstract

The Janus kinase (JAK) pathway is implicated in the pathogenesis of many inflammatory and autoimmune diseases including rheumatoid arthritis (RA), psoriasis, and inflammatory bowel disease. There are a lot of proinflammatory cytokines involved in such diseases using this pathway to transduce intracellular signals. In the last years, JAK inhibitors (jakinibs) have appeared with a great success, showing that these kinds of drugs have a great applicability in clinical practice. Tofacitinib and baricitinib, the first jakinibs approved for the treatment of RA, are being investigated also for treating other autoimmune systemic diseases. Likewise, other jakinibs are in several phases of development. This review analyses the safety and clinical efficacy of the jakinibs, starting with the classics and continuing with next-generation jakinibs.

Keywords: Adverse reactions; Efficacy; Eficacia; Inhibidores de las proteínas Janus cinasa; Interacciones farmacológicas; Janus kinase inhibitors; Pequeñas moléculas; Pharmacological interactions; Reacciones adversas; Small molecule drugs.